Runben Biotechnology Co (SHSE:603193) Total Liabilities: ¥158 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Runben Biotechnology Co Ltd SHSE:603193

72 GF Score

Price ¥21.96

GF Value ¥28.26

Valuation Modestly Undervalued

2 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Runben Biotechnology Co Total Liabilities?

Runben Biotechnology Co SHSE:603193 -1.79% 72 Total Liabilities is ¥158 Mil as of Mar. 2026. GuruFocus rates SHSE:603193 with a GF Score™ of 72/100 and a GF Value™ of ¥28.26 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Runben Biotechnology Co's Total Liabilities for the quarter that ended in Mar. 2026 was ¥158 Mil.

Runben Biotechnology Co's quarterly Total Liabilities declined from Sep. 2025 (¥134.06 Mil) to Dec. 2025 (¥116.79 Mil) but then increased from Dec. 2025 (¥116.79 Mil) to Mar. 2026 (¥158.21 Mil).

Runben Biotechnology Co's annual Total Liabilities increased from Dec. 2023 (¥97.61 Mil) to Dec. 2024 (¥138.88 Mil) but then declined from Dec. 2024 (¥138.88 Mil) to Dec. 2025 (¥116.79 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Runben Biotechnology Co Total Liabilities Related Terms

Runben Biotechnology Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Runben Biotechnology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Runben Biotechnology Co Total Liabilities Chart

Runben Biotechnology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

84.69

102.83

97.61

138.88

116.79

Runben Biotechnology Co Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial														176.92	163.26	134.06	116.79	158.21

72GF Score

Runben Biotechnology Co Ltd SHSE:603193

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Runben Biotechnology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Runben Biotechnology Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	112.878	+	(0	+	3.911
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	117

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	2337.769	-	2220.98
	=	117

Runben Biotechnology Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	154.386	+	(0	+	3.819
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	158

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	2431.821	-	2273.616
	=	158

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of ¥158 Mil mean?

Runben Biotechnology Co (SHSE:603193) has a Total Liabilities of ¥158 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Runben Biotechnology Co and its competitors.

Is Runben Biotechnology Co's Total Liabilities too high?

Runben Biotechnology Co's current Total Liabilities is ¥158 Mil. Overall, Runben Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Runben Biotechnology Co's Total Liabilities compare to PG and CL?

Runben Biotechnology Co's Total Liabilities of ¥158 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Consumer Packaged Goods company?

A good Total Liabilities depends on the Consumer Packaged Goods industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Runben Biotechnology Co and its competitors. Runben Biotechnology Co's current Total Liabilities is ¥158 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Runben Biotechnology Co stock overvalued right now?

Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.26, compared to a current price of ¥21.96 — trading 22.3% below its estimated fair value. The current Total Liabilities is ¥158 Mil. Runben Biotechnology Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Total Liabilities is ¥158 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?

Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued. The current stock price of ¥21.96 is trading 22.3% below its estimated GF Value™ of ¥28.26. GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:603193:

Total Liabilities: ¥158 Mil
GF Value™: ¥28.26 vs. price of ¥21.96 (22.3% below fair value)
GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →